Study of a Single Primary Dose Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV®) in Healthy Subjects

NCT02492165 · clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
250
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Sanofi Pasteur, a Sanofi Company

Collaborators